Allergan will pay $2.9bn in cash for LifeCell, a division of Acelity, adding its first regenerative medicine portfolio and marking its first commercial-stage deal in more than a year. The company hopes to exploit the surgical products for aesthetic uses beyond breast reconstruction.
Allergan PLC will pay Acelity LP Inc. $2.9bn to buy the LifeCell Corp. portfolio of aesthetic and surgical products, marking Allergan’s first regenerative medicine transaction and its first acquisition of a firm with commercial-stage assets since the company bought Kythera Biopharmaceuticals Inc. last year.
Investors have punished Allergan for its development-stage acquisitions this year, sending the company’s stock below $200 per share for the...
Emerging Company Profile: Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.
The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.
Deal Snapshot: Jazz, which sells Epidiolex for rare seizure disorders, will pay $42.5m up front to take over development of Saniona’s preclinical Kv7.2/Kv7.3 activator SAN2355 for epilepsy.
Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.
Deal Snapshot: Jazz, which sells Epidiolex for rare seizure disorders, will pay $42.5m up front to take over development of Saniona’s preclinical Kv7.2/Kv7.3 activator SAN2355 for epilepsy.
Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.
All eyes on chronic urticaria after eosinophilic esophagitis disappointment.
